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Tumour localisation with polyclonal antibodies
directed against CEA, in xenografts of human
colon carcinomas, was first demonstrated by
Primus et al. (1973) and Goldenberg et al. (1974)
using organ counting and photoscanning
techniques. More recently studies demonstrating
successful localisation (Colcher et al., 1983; Herlyn
et al., 1983 and Pimm & Baldwin, 1984) and
immuno-radiotherapy (Zalcberg, 1984) in the
human tumour xenograft using monoclonal
antibodies against various tumour markers have
been reported. In most studies the paired labelling
technique of Pressman et al. (1957) has been
adopted enabling the dynamics of distribution and
clearance of specific anti-tumour antibodies to be
compared with normal immunoglobulin. The
xenograft model is particularly useful for providing
a measure of the potential of the antibody for both
diagnostic imaging of tumours and for therapy
since it indicates the amount of specific antibody
retained by tumour and its residence time. This
helps to define its effective half-life and dosimetry
for optimal therapeutic administration.
In the present work, described here in
preliminary form, we have used the paired
distribution method to evaluate a monoclonal
antibody (1H12) which is directed against CEA.
This IgG-1 antibody has been chosen for its high
specificity for CEA and lack of cross-reactivity with
human granulocytes and red cells. In this respect it
is similar to the monoclonal antobody (MAb 35)
described by Buchegger et al. (1983) which is
effective in the localisation of colo-rectal tumours.
1H12 was purified from mouse ascites fluid, in
yields of 800-1000pgml-1, by affinity chromato-
graphy on CEA-Sepharose. After radio-iodination
by the chloramine T method, to a specific activity
of 6pCipg -1, lH12 was shown to bind to MAWI
colon tumour cells (see below) by solid phase assay
and to purified CEA by double antibody radio-
immunoassay and SDS-polyacrylamide electro-
phoresis followed by the Western blot procedure.
In vivo studies were carried out in nude mice bearing
the xenograft line MAWI, derived from a human
mucoid adenocarcinoma of the colon expressing
moderate amounts of CEA (Lewis et al., 1983).
Tumour weights were between 200 and 500 mg. For
each localisation expenrment 4pg 125I-1H12 and
4 pg non-specific 131I-IgG were administered i.v.
to groups of 4 tumour bearing and 3 control mice
without implanted tumours. Groups were sacrificed
for tissue counting at 1, 2, 4 and 7h, and 1, 2, 3,
7, 9 and 12 days post injection. The results were
expressed as the mean percentage of injected anti-
body g 1 tissue for each experimental group.
The tissue distribution of 1H12 from 1 to 24h is
shown in Figure 1. With the non-excretory tissues -
stomach, colon, bone and muscle (Figure la) - a
marked accumulation of H12 occured in the first
4h. The amount of lH12 in these organs then fell
gradually to just over 1% of the injected dose by
24h. In the same time period (1-24h) the amount
of lH12 in the blood fell from 41% to 12% of the
injected dose. Similar results were obtained for the
control mice (data not shown). Among the factors
which are likely to determine the accumulation of
1H12 and its subsequent decline in these normal
tissues are its concentration in the blood pool, the
rate of transport of antibody acrosss the capillary
endothelial membranes and the lymphatic drainage
of antibody from the tissues.
As expected the amounts of 1H12 and normal Ig
in the richly perfused organs of the reticulo-
endothelial system and kidney were initially much
higher than in other normal tissues (Figure lb)
only falling to below 1% of the injected dose by
day 4. However the amounts of 1H12 in tumour
exceeded the level in all normal organs except
blood after day 1.
Tumour uptake of lH12 during the first 7h was
almost 5% of the injected dose, similar to that
found in the non-excretory normal organs (Figure
la). However, whereas the concentration of IH12
in these organs fell to 1% of the injected dose by
24h, the amount in the tumour remained at the
higher level. Tumour localisation with IH12 is
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Our studies have also shown that lH12 may
remain in the tumour at maximal levels at least up
to 12 days after injection (Figure 2). During this
period a gradual increase in the uptake ofantibody by
tumourwasnotedreaching6.3% oftheinjecteddoseat
day 9 and falling off slightly by day 12. This latent
accumulation may be the result of the continued
excretion or re-expression of CEA at the tumour cell
surfacewhichhas been reported to takeplaceevery6h
(Rosenthal etal., 1980). It would however be expected
tobelimited bythe reducedlevelsofIH12intheblood
(Figure 2).
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Figure 1 (a) Distribution of 1251-1H12 in non-
excretory normal organs (muscle (0); colon (El) and
stomach (A)) and in tumour (0) and (b) in excretory
and reticuloendothelial organs (lung (0); liver (EO)
spleen (A) and kidney (@)) from 1 to 24h. Each time
point shows the mean value +s.e. for the percentage
of the injected antibody present in 1 g tissue for each
group of animals. The curve for bone was similar to
that for colon and has been omitted for clarity.
therefore dependent on its retention by, or
detention in, this tissue and not on a preferential
uptake. Non-specific Ig showed a similar
distribution pattern to 1H12 falling to
- 1% of the
injected dose at 24h in the normal organs but
remaining at -1.8% in the tumour (data not
shown). This is consistent with a limited localising
potential previously seen with non-specific IgG
(Goldenberg et al., 1974; Mach et al., 1974). The
immunological specificity of 1H12 may account for
its increased concentration at the tumour site
compared to non-specific IgG. It is possible that
1 H 12-CEA immune complexes as well as Fc-
receptor complexes are formed the escape of which
is delayed from the tumour site.
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Figure 2 Distribution of 125l-1H12 in blood (0) and
tumour (0) from 1-12 days as the mean ofthe injected
antibody dose g tissue.
Prolonged retention of a radiolabelled anti-
tumour antibody is important since it increases the
effective half-life and radiation dose received by
individual tumour cells. The results reported here
suggest that IH12 is a strong candidate for therapy
trials. Prolonged retention of an antibody in
tumour appears not to adveresely effect its
clearance from normal organs. This is seen with
IH12 where the tumour:blood ratio rose steadily
from 0.04:1 at 1 h to over 3:1 at 12 days (Figure 3).
Our results are similar to those reported by
Colcher et al. (1984) for an unrelated antibody
which remained in tumour up to 19 days after
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Figure 3 Tumour:blood ratios for 125I-labelled 1H12
at time points 1 h to 12 days. The data represents the
mean value +s.e. for each group of mice.
injection. This contrasts with previous reports using
monoclonal antibodies to various tumour markers
where optimal tumour localisation was between 3
and 7 days (Mach et al., 1974; Hedin et al., 1982;
Buchegger et al., 1983; Herlyn et al., 1983 and
Zalcberg et al., 1983).
In conclusion these studies have provided new
information concerning the dynamics of distribution
for a monoclonal anti-CEA antibody from 1 h to
12 days. It will be important to study the effect of
escalating and sequential doses in relation to
therapy and the results here should facilitate the
design and interpretation of such experiments.
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